Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2020 Oct;6(10):1192-1198.
doi: 10.1016/j.eng.2020.03.007. Epub 2020 Mar 18.

Experimental Treatment with Favipiravir for COVID-19: An Open-Label Control Study

Qingxian Cai  1 , Minghui Yang  1 , Dongjing Liu  1 , Jun Chen  1 , Dan Shu  1 , Junxia Xia  1 , Xuejiao Liao  1 , Yuanbo Gu  1 , Qiue Cai  1 , Yang Yang  1 , Chenguang Shen  1 , Xiaohe Li  1 , Ling Peng  1 , Deliang Huang  1 , Jing Zhang  1 , Shurong Zhang  1 , Fuxiang Wang  1 , Jiaye Liu  1 , Li Chen  1 , Shuyan Chen  1 , Zhaoqin Wang  1 , Zheng Zhang  1 , Ruiyuan Cao  2 , Wu Zhong  2 , Yingxia Liu  1 , Lei Liu  1
Affiliations

Experimental Treatment with Favipiravir for COVID-19: An Open-Label Control Study

Qingxian Cai et al. Engineering (Beijing). 2020 Oct.

Abstract

There is currently an outbreak of respiratory disease caused by a novel coronavirus. The virus has been named severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and the disease it causes has been named coronavirus disease 2019 (COVID-19). More than 16% of patients developed acute respiratory distress syndrome, and the fatality ratio was 1%-2%. No specific treatment has been reported. Herein, we examined the effects of favipiravir (FPV) versus lopinavir (LPV)/ritonavir (RTV) for the treatment of COVID-19. Patients with laboratory-confirmed COVID-19 who received oral FPV (Day 1: 1600 mg twice daily; Days 2-14: 600 mg twice daily) plus interferon (IFN)-α by aerosol inhalation (5 million international unit (IU) twice daily) were included in the FPV arm of this study, whereas patients who were treated with LPV/RTV (Days 1-14: 400 mg/100 mg twice daily) plus IFN-α by aerosol inhalation (5 million IU twice daily) were included in the control arm. Changes in chest computed tomography (CT), viral clearance, and drug safety were compared between the two groups. For the 35 patients enrolled in the FPV arm and the 45 patients in the control arm, all baseline characteristics were comparable between the two arms. A shorter viral clearance median time was found for the FPV arm versus the control arm (4 d (interquartile range (IQR): 2.5-9) versus 11 d (IQR: 8-13), P < 0.001). The FPV arm also showed significant improvement in chest CT compared with the control arm, with an improvement rate of 91.43% versus 62.22% (P = 0.004). After adjustment for potential confounders, the FPV arm also showed a significantly higher improvement rate in chest CT. Multivariable Cox regression showed that FPV was independently associated with faster viral clearance. In addition, fewer adverse events were found in the FPV arm than in the control arm. In this open-label before-after controlled study, FPV showed better therapeutic responses on COVID-19 in terms of disease progression and viral clearance. These preliminary clinical results provide useful information of treatments for SARS-CoV-2 infection.

Keywords: Antiviral therapy; COVID-19; Favipiravir; Open-label nonrandomized control study; SARS-CoV-2.

PubMed Disclaimer

Figures

Fig. 1
Fig. 1
Score of chest CT scan for a 56-year-old female patient with COVID-19 from the FPV arm. (a–c) show parts of the CT images obtained prior to the FPV treatment, which were scored as 15 according to the scoring method. (d–f) show parts of the CT images obtained on Day 12 after the FPV treatment, which were scored as 6.
Fig 2
Fig 2
Flowchart for the present trial. (FPV: LPV/RTV).
Fig 3
Fig 3
Kaplan–Meier survival curves for the length of time until viral clearance for both kinds of antiviral therapy (P < 0.001).
Fig 4
Fig 4
Time of viral clearance and improving chest CT scan on Day 14 after treatment.
See this image and copyright information in PMC

References

    1. Wang D., Hu B., Hu C., Zhu F., Liu X., Zhang J. Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan, China. JAMA. 2020;323(11):1061–1069. - PMC - PubMed
    1. Huang C., Wang Y., Li X., Ren L., Zhao J., Hu Y. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020;395(10223):497–506. - PMC - PubMed
    1. Li Q., Guan X., Wu P., Wang X., Zhou L., Tong Y. Early transmission dynamics in Wuhan, China, of novel coronavirus-infected pneumonia. N Engl J Med. 2020;382:1199–1207. - PMC - PubMed
    1. Chen N., Zhou M., Dong X., Qu J., Gong F., Han Y. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. Lancet. 2020;395(10223):507–513. - PMC - PubMed
    1. National Health Commission of the People’s Republic of China. Daily briefing on novel coronavirus cases in China [Internet]. Beijing: National Health Commission of the People’s Republic of China; c2020 [updated 2020 Mar 12; cited 2020; c2020 Feb 25]. Available form: http://en.nhc.gov.cn/DailyBriefing.html.